Assessment of nonsteroidal anti-inflammatory drug-induced hepatotoxicity
- 8 April 2011
- journal article
- review article
- Published by Informa Healthcare in Expert Opinion on Drug Metabolism & Toxicology
- Vol. 7 (7), 817-828
- https://doi.org/10.1517/17425255.2011.574613
Abstract
Introduction: Liver toxicity related to NSAIDs is of outstanding importance because of the wide use of these drugs. NSAIDs are responsible for roughly 10% of the total of cases of drug-induced hepatotoxicity. The assessment of NSAID-induced hepatotoxicity, presently based on clinical and analytical biomarkers, is critical for early diagnosis and immediate withdrawal of the causing drug. Areas covered: The review presents an overview of current knowledge of the assessments of NSAID-induced hepatotoxicity with emphasis on the causative drugs, the NSAID-specific mechanisms involved, and a summary of genetic and non-genetic risk factors. Additionally, the authors discuss genetic factors which show NSAID-specific risk, namely CYP2C, UGT2B7, GSTM1 and GSTT1, as well as HLA alleles. The paper includes a list of the NSAID 'usual suspects' that cause hepatotoxicity based on the integrated information of drug-induced hepatotoxicity databases. Expert opinion: The ultimate goal of this research is pre-prescription testing. Unfortunately, genetic testing, alone, is not sufficient to predict NSAID-induced hepatotoxicity. The development of genetic biomarkers capable of identifying at-risk individuals will not be complete until we develop the ability to fully characterize patients' phenomes and the phenome-genome interaction in patients with NSAID-induced hepatotoxicity. Additionally, a characterization of the metabolic profile of the causative drug in patients with NSAID-induced hepatotoxicity would add crucial information which is presently disregarded in most studies. The full development of robust biomarkers will require the combination of several disciplines including causal statistics, phenomics, genomics, transcriptomics and metabonomics.Keywords
This publication has 86 references indexed in Scilit:
- Keratin Variants Predispose to Acute Liver Failure and Adverse Outcome: Race and Ethnic AssociationsGastroenterology, 2010
- Risk Factors for Idiosyncratic Drug-Induced Liver InjuryGastroenterology, 2010
- Oxidative stress is important in the pathogenesis of liver injury induced by sulindac and lipopolysaccharide cotreatmentToxicology, 2010
- Drugs Associated with Hepatotoxicity and their Reporting Frequency of Liver Adverse Events in VigiBase™Drug Safety, 2010
- Drug-induced liver injury: a clinical updateCurrent Opinion in Gastroenterology, 2010
- Acetaminophen dosing of humans results in blood transcriptome and metabolome changes consistent with impaired oxidative phosphorylationHepatology, 2009
- Phenotypic characterization of idiosyncratic drug-induced liver injury: The influence of age and sexHepatology, 2009
- Causes, Clinical Features, and Outcomes From a Prospective Study of Drug-Induced Liver Injury in the United StatesGastroenterology, 2008
- Genetic polymorphisms of CYP2C9 and CYP2C19 are not related to drug‐induced idiosyncratic liver injury (DILI)British Journal of Pharmacology, 2007
- Idiosyncratic drug hepatotoxicityNature Reviews Drug Discovery, 2005